Ocugen, Inc. (OCGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 26, 2019 (filed October 1, 2019), details the completion of a business combination between Histogenics Corporation and Ocugen, Inc. Effective September 27, 2019, Histogenics merged with Ocugen, with Ocugen surviving as a wholly-owned subsidiary. The company changed its name to Ocugen, Inc., and its ticker symbol on the Nasdaq Capital Market changed from HSGX to OCGN. The company is a clinical-stage biopharmaceutical firm focused on therapies for rare and underserved eye diseases.
Key Financial Metrics and Capital Structure
- Private Placement: Completed a Pre-Merger Financing raising an aggregate purchase price of approximately $25.0 million from accredited investors.
- Asset Sale: Entered an amendment to sell substantially all assets of the NeoCart program to Medavate Corp. for a cash payment of $6.5 million, with a closing date set for October 4, 2019.
- Debt Repayment: Repaid and cancelled bridge loans totaling $5.29 million using proceeds from the private placement.
- Share Capital:
- Executed a 1-for-60 reverse stock split immediately prior to the merger.
- Increased authorized common stock from 100,000,000 to 200,000,000 shares.
- Post-merger outstanding shares: Approximately 11.5 million (excluding ~2.2 million shares held in escrow).
- Former Ocugen stockholders own approximately 86.24% of the fully-diluted common stock.
- Revenue/Profit: The filing does not provide specific revenue, profit, or cash flow figures for the reporting period.
Material Changes and Agreements
- Merger Completion: Histogenics Corporation effectively ceased to exist as a public entity, adopting Ocugen's business and name. The exchange rate was 0.4794 shares of new Common Stock for each share of Ocugen common stock.
- Strategic Partnership: Entered a co-development and commercialization agreement with CanSino Biologics Inc. regarding the gene therapy candidate OCU400.
- CanSinoBIO holds exclusive rights in China, Hong Kong, Macau, and Taiwan.
- Ocugen retains exclusive rights globally outside the CanSinoBIO territory.
- CanSinoBIO will handle Chemistry, Manufacturing, and Controls (CMC) for clinical supplies.
- Agreement includes mutual royalty payments based on net sales (mid-to-high single digits for CanSinoBIO territory; low-to-mid single digits for Ocugen territory).
- Leadership Changes:
- Former Histogenics directors and officers resigned.
- Shankar Musunuri appointed Chairman and CEO.
- Sanjay Subramanian appointed Chief Financial Officer (effective October 1, 2019) with a base salary of $325,000 and a target bonus of 30%.
- Seven new directors appointed to the Board.
Outlook, Risks, and Contingencies
- Escrow Contingency: Approximately 2.2 million shares of Common Stock are held in escrow. These will be released to investors if the volume-weighted average trading price for the first three trading days post-closing is lower than the price paid by investors for the initial shares.
- Asset Sale Closing: The $6.5 million asset sale to Medavate Corp. is contingent on closing on October 4, 2019.
- Dilution Risk: The increase in authorized shares to 200 million creates potential for future dilution, though the Board has no current plan to issue these additional shares.
- Operational Focus: The company is transitioning to a clinical-stage biopharmaceutical model, relying on the development of OCU400 and other pipeline assets.
Key Facts for Investor Verification
- Verify the trading price of OCGN on September 30, 2019, to determine if the 2.2 million escrowed shares will be released to investors.
- Confirm the closing of the $6.5 million NeoCart asset sale to Medavate Corp. on October 4, 2019.
- Review the full text of the CanSino Biologics agreement for specific milestones and royalty calculation details.
- Monitor the filing of the Form 10-Q for the quarter ended September 30, 2019, for pro forma financial information and the full employment agreement for the new CFO.
- Check the status of the 1-for-60 reverse stock split adjustment in brokerage accounts.